Computational Drug Safety & PKPD Modeling - software & AI news

Daily news on software, AI, and companies shaping computational drug safety & pkpd modeling.

Showing 29 results
Press release cover image

Nov 4, 2026

New Research Suggests hERG IC₁₀ May Improve Prediction of Drug-Induced QT Prolongation

NEW ORLEANS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Dr. William J. Crumb Jr., Ph.D., President and CEO of Nova Research Laboratories, LLC, has collaborated with Dr. Andrew G. Edwards, Ph.D., Chief Research Scientist of Simula Research Laboratory in Oslo, Norway and COO of Organos in Berkely, California, on a new publication titled “Predicting thorough QT safety profile using hERG IC10 versus IC50.” Published in the Journal of Pharmacological and Toxicological Methods, the study examines an alternat
A minimalist representation of a database icon and data flow in a laboratory context.

Nov 4, 2026

Charles River teams up with Ipsen to use virtual control groups in toxicology studies

Charles River Laboratories has partnered with Ipsen to leverage its virtual control group (VCG) database in toxicology studies, aiming to enhance the efficiency and ethical standards of safety assessments.The collaboration focuses on integrating VCG data into Ipsen’s good laboratory practice-compliant toxicology study. This innovative approach seeks to reduce reliance on live animal subjects by using historical data to inform study outcomes, potentially streamlining timelines and improving data
Press release cover image

Nov 3, 2026

Differentia Bio Advances Human Digital Twins with AI-Driven Disease Modeling and Clinical Validation

From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharmaceutical R&D.SAN FRANCISCO, Nov. 3, 2026 /PRNewswire/ -- Differentia Bio, a developer of AI-powered human disease digital twins, today announced that therapeutic mechanisms identified by its disease modeling platform in 2023–2024 have since gained support from independent clinical evidence, including an FDA-approved treatment and emerging
Press release cover image

Oct 29, 2026

Latus Bio Announces the Publication of a Predictive Computational Model of Huntington’s Disease (HD) Built on Human Data Along with Validating Preclinical Data, Supporting LTS-201 as a Potential Best-in-Class, Disease-Modifying Therapy for HD

Published in Nature Communications, the study offers the first unified model of HD pathogenesis and offers insights that could lead to the development of improved therapiesComputational model built from human natural history and human neuronal-somatic-expansion data simulates long-term impact of therapies designed to suppress somatic instability (SI), predicting substantial slowing of cUHDRS decline and delays in motor symptom onset in HDInformed by model-predicted thresholds for therapeutic act
A minimalist representation of a virtual patient model and an implant in flat design.

Oct 28, 2026

Leeds medtech spinout adsilico raises £10m for virtual patient technology

Leeds-based medtech spinout adsilico has secured £10 million in funding to enhance its AI-driven virtual patient technology aimed at optimizing medical device testing.This Series A investment will enable adsilico to expand its computer-generated patient models, which allow manufacturers to evaluate the performance of implants across diverse populations prior to initiating clinical trials. This innovation seeks to address the shortcomings of traditional medical device testing, where participant d
Press release cover image

Oct 22, 2026

Insilica and ProtoQSAR Integrate ProtoPRED® into ToxIndex to Advance Chemical Safety Assessment

The partnership brings more than 60 ProtoPRED® predictive models to the 150+ computational tools in ToxIndex, supporting faster, more transparent and efficient in silico assessments.ROCKVILLE, Md. and VALENCIA, Spain, Oct. 22, 2026 /PRNewswire/ -- Insilica, Inc., developer of the ToxIndex chemical safety intelligence platform, and ProtoQSAR SL, a computational chemistry company specializing in predictive toxicology, today announced a technology integration and distribution agreement. The integra
Press release cover image

Oct 20, 2026

PrecisePK Marks 40+ Years of Precision Dosing, Highlights EHR Integrations Driving Safer Pharmacist Workflows

Celebrating four decades of precision dosing, PrecisePK connects directly to Epic, Cerner, and Sentri7 so patient data comes to clinicians and more time goes to patient care.SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- PrecisePK, a therapeutic drug monitoring (TDM) software company used by hospital systems worldwide, is highlighting its electronic health record (EHR) and clinical surveillance integrations this year, building on more than 40 years of precision dosing experience since launching from U
Press release cover image

Oct 9, 2026

Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin

Collaboration will apply Turin to explore mechanistic QSP model structures at scale and bring insights to development decisions where traditional modeling timelines have limited their useRESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to a
Press release cover image

Oct 8, 2026

IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today at TechIQ 2026 introduced IQVIA Life Science ModelsTM to help predict clinical trial outcomes.IQVIA Life Science Models are a suite of purpose-built models for life sciences, combining IQVIA’s proprietary expert content, deep domain knowledge and established regulatory, compl
Press release cover image

Oct 7, 2026

insitro Designed Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insitro built with Eli Lilly and Company (Lilly) to predict in vitro and, critically, in vivo properties of small molecules can now be used by certain biotech companies in Lilly TuneLab™. Trained on multi-species preclinical data that Lilly generated over decades of research from hu
A minimalist representation of a cell and genetic changes in flat design.

Oct 6, 2026

New Calibration Framework Improves Confidence in AI Virtual Cell Models

A recent study has revealed that AI virtual cell models can more accurately predict cellular responses to genetic changes than previously believed, particularly when using more sensitive evaluation metrics. This research, conducted by Shift Bioscience and collaborators, emphasizes the importance of calibration in assessing model performance.The study, published in *Nature Biotechnology*, introduces a new framework that includes a positive-control baseline to evaluate whether common metrics can e
Press release cover image

Oct 5, 2026

Chungnam National University Researchers Develop Model for Predicting Growth Hormone Therapy Responses in Children With Short Stature

The predictive modeling approach can help pediatricians simulate different dosage regimens and explore predicted growth trajectories under various treatment scenariosDAEJEON, South Korea, Oct. 5, 2026 /PRNewswire/ -- Idiopathic short stature (ISS) describes children whose height is substantially below the expected range for their age and sex without any identifiable medical cause. Recombinant growth hormone (GH) therapy is often used to support growth, but responses vary widely. While some child